Well it's a biotech and the product is in phase 3, but it is still highly speculative. And also, another member here at ET who is quite versed and well respected, pm'd me and basically said the board was a bunch of idiots and whoever they are using for their testing are idiots too... so there's that. And this guy wouldn't say that lightly. But the op wanted a 33:1 return, and there are only two ways that can be done in a short period of time... either a biotech that gets the approval on one of their candidates with a very large tam, or a one sided directional option call way out of the money that you buy for pennies and hope you're right on the direction and magnitude of the move. A biotech play is probably easier, but as these things go, you need to really follow the company and know what's going on. Conference calls, cash burn, etc. Subscribe to their investor relation's dept. email and get any updates the moment they come out. But once again, knowing what is going on and where they stand with things is crucial before any email alerts can help you. Biotechs are tricky. Q over Q cash burn on a boutique operation is very important, as it applies to their balance sheet and any secondary rounds they might institute. That keeps the overhead low. You're a piece of work.
Big trouble at CANO : CEO, 3 directors resign and stock loses about 20% : https://finance.yahoo.com/news/cano-health-comments-resignation-directors-113800116.html Luckily I was not invested in this yet, as I had others with higher rankings in the watchlist. OTOH the mentioned GOEV does well so far (not to be confused with the similar company EVGO (operator of EV fast charging stations network), which btw seems to do even better).
Looks like it was the reverse of a pump and dump...lol. or its now a pump and dump news.. either way its higher then when the Friday news came out. stock was at 1.18 then